What is Innovative Cellular Therapeutics?
Innovative Cellular Therapeutics is a clinical-stage biotechnology firm dedicated to advancing cancer treatment through innovative CAR-T therapies. The company's proprietary platforms, CoupledCAR and INSTACAR, are central to its research and development efforts, particularly for solid tumors. ICT's leading product candidate, GCC19CART, is designed to combat relapsed/refractory metastatic colorectal cancer. By expanding its CAR-T candidate portfolio and leveraging the ARMORED CAR platform, ICT aims to enhance the effectiveness of cellular immunotherapies for a range of solid tumors, offering new hope to patients battling cancer.
How much funding has Innovative Cellular Therapeutics raised?
Innovative Cellular Therapeutics has raised a total of $28.6M across 1 funding round:
Other Financing Round
$28.6M
Other Financing Round (2019): $28.6M with participation from LH Ventures
Key Investors in Innovative Cellular Therapeutics
LH Ventures
LH Ventures is an investment firm that participated in this funding round. Further details on their specific investment focus are not available.
What's next for Innovative Cellular Therapeutics?
The substantial enterprise-level backing and recent strategic investment position Innovative Cellular Therapeutics for accelerated growth and the advancement of its clinical pipeline. This capital infusion is expected to fuel further research and development, potentially enabling ICT to expand its therapeutic reach into new cancer indications and solidify its market presence. The company's focus on solid tumors with its advanced CAR-T platforms suggests a strategic push to address unmet needs in a challenging area of oncology, paving the way for potential future commercialization and significant impact on patient outcomes.
See full Innovative Cellular Therapeutics company page
